Lucid Diagnostics Q2 Loss Widens; Going Concern Doubt Persists

summarizeSummary

Lucid Diagnostics posted a wider Q2 loss and reiterated going concern doubt, with a key debt waiver expiring August 22. Heavy dilution from offerings and preferred conversions added over 59 million shares in six months.

check_boxKey Events · Earnings and Guidance · LUCD

• Q2 Loss Widens to $14.7M

  Net loss attributable to common stockholders was $14.7 million for Q2 2026, up from $7.9 million in Q2 2025, driven by higher sales and marketing spend.

• Going Concern Doubt Reiterated

  Management again stated substantial doubt about the company's ability to continue as a going concern within one year, citing recurring losses and negative operating cash flow.

• Debt Waiver Expires August 22

  A waiver from 2024 Convertible Note holders covering the missed Medicare coverage milestone expires August 22, 2026; failure to extend could trigger default.

• Heavy Dilution in H1 2026

  Shares outstanding rose to 190.8 million from 131.1 million at year-end, driven by an 18-million-share registered direct offering at $1.00, ATM sales, and preferred stock conversions.

auto_awesomeAnalysis · LUCD · Industrial Applications And Services

Lucid Diagnostics reported a Q2 net loss of $14.7 million attributable to common stockholders, up from $7.9 million a year ago, while revenue grew 27% to $1.5 million. The company reiterated substantial doubt about its ability to continue as a going concern, with only $33.4 million in cash and a $23.5 million convertible note liability classified as current. A waiver from noteholders covering a missed Medicare coverage milestone expires August 22, 2026, leaving near-term default risk. The quarter also saw heavy dilution: an 18-million-share registered direct offering at $1.00 and ATM sales added over 22 million shares, while preferred stock conversions and dividends pushed total shares outstanding to 190.8 million from 131.1 million at year-end.